Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Market Cap	2.67B -8.3%
Revenue (ttm)	222.03M +69.9%
Net Income	24.99M +72.3%
EPS	0.45 +28.4%
Shares Out	58.09M
PE Ratio	101.50
Forward PE	n/a
Dividend	0.25 (0.51%)
Ex-Dividend Date	Jul 20, 2026

Volume	71,291
Open	48.40
Previous Close	48.00
Day's Range	45.40 - 48.40
52-Week Range	46.00 - 89.85
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Pet Pharm Biotech

Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7762

Financial Performance

In 2025, Pet Pharm Biotech's revenue was 222.03 million, an increase of 69.88% compared to the previous year's 130.70 million. Earnings were 24.99 million, an increase of 72.25%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 30, 2026

Data Sources Report a data error